Session Information

  • WCLC 2020

    2020 World Conference on Lung Cancer

    Conference Program for the 2020 World Conference on Lung Cancer in Singapore


    Presentation Date(s):  
    • January 28 - 31, 2021
    • Total Presentations: 1597

    All times listed are in Singapore time (GMT+8)

    PL - Plenary
    PS - Presidential Symposium
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    IS - Industry Symposium
    JICC - Joint IASLC-CAALC-CSCO Session

Filter Results:

Show Only CME Accredited Sessions

  • +

    P47 - Small Cell Lung Cancer/NET - Biology / Translational

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Small Cell Lung Cancer/NET
    • +

      P47.14 - Clinicopathologic Features of Large Cell Neuroendocrine Carcinoma of Lung

      00:00 - 00:00  |  Presenter: Perran Fulden Yumuk

      • Abstract

      Loading...

  • +

    P84 - Targeted Therapy - Clinically Focused - ALK

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • +

      P84.03 - GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients

      00:00 - 00:00  |  Presenter: Nir Peled

      • Abstract

      Loading...

  • +

    PS01 - Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)

    • 07:00 - 09:00
    • 1/30/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PS01.09 - Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598

      08:08 - 08:18  |  Presenter: Michael Boyer

      • Abstract

      Loading...

  • +

    PS02 - Presidential Symposium (Re-Broadcast) (Japanese, Mandarin, Spanish Translation Available)

    • 18:00 - 20:00
    • 1/30/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PS02.09 - Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598

      19:08 - 19:18  |  Presenter: Michael Boyer

      • Abstract

      Loading...